Double-Action Antibiotic Advances In GSK's Pipeline
Dosing Starts In Phase III Gepotidacin Studies
GlaxoSmithKline has initiated Phase III studies, EAGLE-1 and EAGLE-2, of potentially a new chemical class of oral antibiotic in patients with infections of public health concern, gonorrhea and urinary tract infections.
